Please assess the completion status of the following clinical trial:

Trial Title: Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA as defined by 1987 American College of Rheumatology (ACR) criteria~* Functional Class I, II, or III RA as defined by 1987 ACR criteria~* Serum C-reactive protein (CRP) measurement of greater than 5 mg/L~* Mildly active disease with at least one swollen and two tender joints, but no more than six swollen and eight tender joints~* If on corticosteroids, dose must be stable and 10 mg/day prednisone (or equivalent) or less for at least 4 weeks prior to study entry~* If on DMARD, dose must be stable for at least 4 weeks (methotrexate, leflunomide, azathioprine, etanercept, adalimumab, anakinra) or at least 3 months (hydroxychloroquine, gold, or abatacept)~* Willing to use acceptable means of contraception~Exclusion Criteria:~* Serum creatinine level greater than 1.5 mg/dL~* Currently taking a statin or have taken a statin within 12 weeks of study entry~* History of an adverse reaction to a statin~* Active or recent infection within 4 weeks of study entry~* Myositis or an unexplained elevation in creatine phosphokinase (CPK)~* Joint replacement surgery within 60 days of study entry or plan to undergo joint replacement surgery during the course of the study~* Intra-articular cortisone injections within 4 weeks of study entry~* Chronic disorders other than RA affecting the joints, including systemic lupus erythematosus (SLE), psoriatic arthritis, gout, scleroderma, or known reactive arthritis (Reiter's syndrome)~* HIV infection~* Hepatitis B surface antigen positive~* Hepatitis C antibody positive~* Treatment with infliximab within 12 weeks of study entry~* Treatment with rituximab~* Treatment with medications known to be metabolized by the cytochrome P3A4 pathway. More information about this criterion can be found in the protocol.~* Require amiodarone or verapamil~* Investigational drug or treatment during the 4 weeks or seven half-lives prior to study entry~* History of alcohol abuse~* History of liver disease, current liver disease (e.g., hepatitis, cirrhosis), or abnormal liver function (AST or ALT greater than 2 times the upper limit of normal \[ULN\])~* Any condition that, in the opinion of the investigator, may interfere with the study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lovastatin (Type: EXPERIMENTAL): Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D\&C Yellow #10, FD\&C Blue #1, and Yellow #6 were added as dyes.
- Placebo (Type: PLACEBO_COMPARATOR): Participants are randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188.

Based on this trial design, predict the completion outcome and termination type (if applicable).